ASX hopeful HaemaLogiX is ‘fully ready’ for its $30m IPO. Almost.
After more than 20 years developing its blood cancer immunotherapies, HaemaLogiX is preparing to kick off its IPO next week. Unless Trump’s Iran war gets in the way.
Sydney-based biotech HaemaLogiX will be ready to hit play on its ASX listing as soon as next week after years of setbacks — but chief executive Chris Baldwin may yet be forced to wait a little longer.
“We’ve been preparing for this for some time,” Baldwin told Capital Brief.
“We expect the company will be ready for the market in about a week. We think the prospectus will be ready. The question only becomes — is the market ready for the company, or any company that’s doing anything slightly novel right now?
“Only time, and Trump, will tell, right?”
HaemaLogiX, which is looking to raise between $20 million and $25 million, develops immunotherapies used to treat multiple myeloma, the second most common form of blood cancer.
The company has hired Ord Minnett and Canaccord Genuity to lead the initial public offering, which was previously slated for this time last year. Lander & Rogers is providing legal support.
